

CLAIMS

1. Use of an anti-VEGFR-2 antibody that specifically binds to VEGFR-2 to neutralize an activity of VEGFR-2 in the preparation of a medicament for treating or alleviating human cerebral edema, in which the human cerebral edema is a glioblastoma surrounding edema, in
5 which the anti-VEGFR-2 antibody comprises:
 - a light chain variable region comprising light chain CDR1 of SEQ ID NO: 1, light chain CDR2 of SEQ ID NO: 2 and light chain CDR3 of SEQ ID NO: 3; and
 - a heavy chain variable region comprising heavy chain CDR1 of SEQ ID NO: 4, heavy chain CDR2 of SEQ ID NO: 5 and heavy chain CDR3 of SEQ ID NO: 6.
- 10 2. Use according to Claim 1, in which the anti-VEGFR-2 antibody comprises:
 - a light chain variable region of SEQ ID NO: 7; and
 - a heavy chain variable region of SEQ ID NO: 8.
3. Use according to Claim 1, in which the composition further comprises one or more selected from the group consisting of osmotic agents, diuretics, glycerols and steroid agents.
- 15 4. Use according to Claim 3, in which the steroid agent is one or more selected among dexamethasone, cortisol, prednisone, prednisolone, methylprednisolone, triamcinolone, corticosterone and desonide.
5. Use according to Claim 1, in which the composition prolongs a survival time of a subject suffering from cerebral edema.
- 20 6. Use of an anti-VEGFR-2 antibody that specifically binds to VEGFR-2 to neutralize an activity of VEGFR-2 in the preparation of a medicament for reducing one or more of dosage and duration of administration of a steroid agent in a subject receiving the steroid agent to treat or alleviate human cerebral edema, in which the human cerebral edema is a glioblastoma surrounding edema, in which the anti-VEGFR-2 antibody comprises:
 - 25 a light chain variable region comprising light chain CDR1 of SEQ ID NO: 1, light chain CDR2 of SEQ ID NO: 2 and light chain CDR3 of SEQ ID NO: 3; and
 - a heavy chain variable region comprising heavy chain CDR1 of SEQ ID NO: 4, heavy chain CDR2 of SEQ ID NO: 5 and heavy chain CDR3 of SEQ ID NO: 6.

7. Use according to Claim 6, in which the anti-VEGFR-2 antibody comprises:
a light chain variable region of SEQ ID NO: 7; and
a heavy chain variable region of SEQ ID NO: 8.
8. Use according to Claim 6, in which the subject is a subject suffering from glioblastoma.
- 5 9. Use according to Claim 6, in which the route of administration of the steroid agent is oral administration.
10. Use according to Claim 6, in which the composition prolongs a survival time of the subject.